Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Centro Nacional De Investigaciones Oncologicas (cnio)

Antonio Rodríguez Hergueta

Jose Ignacio Martín Hernando

Sonia Martínez González

Joaquin Pastor Fernández

Joaquín Pastor Fernández

Carmen Blanco Aparicio

Rosario Concepción Riesco Fagundo

Rosa Maria Álvarez Escobar

David Álvaro Cebrián Muñoz

Francisco Javier Ramos Lima

Ana Belén García García

Rosa Maria Alvarez Escobar

Ana Maria Garcia Collazo

Ana Isabel Hernández Higueras

Beatriz Noya Marino

Carmen Blanco Aparicío

Carl-Gustave Pierre Saluste

Rosa María Álvarez Escobar

Esther Gonzalez Cantalapiedra

Antonio Salgado Serrano

Esther González Cantalapiedra

Joaquin Pastor Fernandez

Ana Belén GARCÍA GARCÍA

David ÁLvaro CEBRIÁN MUÑOZ

Rosa María ÁLvarez Escobar

José Ignacio MARTÍN Hernando

Rosa María Alvarez Escobar

Beatriz Noya Mariño

There is provided compounds of formula I, wherein R1, R, R, R, X, Y, Z, Rand ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. 

Macrocyclic compounds as protein kinase inhibitors

There is provided compounds of formula (I), wherein R, R, Rand Rhave meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I). 

Tricyclic compounds for use as kinase inhibitors

There is provided compounds of formula (I), wherein A, A, A, A, B, B, B, B, B, B, B, Band Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. 

Inhibitors of PI3 kinase

Growing community of inventors

Madrid, Spain

Antonio Rodríguez Hergueta